Astellas Pharma Competitors and Similar CompaniesClear all

Astellas Pharma's competitors and similar companies include Pfizer, Bayer, Urovant Sciences and Hetero.

	Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Bayer Bayer is a life sciences company specializing in healthcare and nutrition.	Urovant Sciences Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions.	Hetero Hetero is a generic pharmaceutical company engaged in the development, manufacturing, and marketing of chemical and biologic drugs.
Founding Date	Founding Date 1923	Founding Date 1849	Founding Date 1863	Founding Date 2016	Founding Date 1993
Type	Type Public	Type Public	Type Public	Type Subsidiary	Type Private
Tags	Tags Healthcare diabetes drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare Manufacturing & Industrial agritech biotech conglomerates drug development life sciences nutrition pharma	Tags Healthcare biotech pharma therapy	Tags Manufacturing & Industrial biotech drug development pharma
Locations	Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Bentley, AU Footscray, AU Mulgrave, AU Sydney, AU see more	Locations Leverkusen, DE HQ Tirana, AL Dely Ibrahim, DZ Luanda, AO Munro, AR Pymble, AU Wien, AT see more	Locations Irvine, US HQ Basel, CH	Locations Hyderabad, IN HQ Norwest, AU Sao Paulo, BR Beijing, CN Nanjing Shi, CN Nanjing Shi, CN Bogotá, CO see more
Employees	Employees 14,754	Employees 88,0006% increase	Employees 92,8152% decrease	Employees 3950% increase	Employees 6,5492% increase
Valuation ($)	Valuation ($) 20.8 b	Valuation ($) 163.9 b	Valuation ($) 27.1 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) ¥1.6t (FY, 2024)	Revenue (est.) $63.6b (FY, 2024)	Revenue (est.) €46.6b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods ¥134.6b (FY, 2024)	Cost of goods $17.9b (FY, 2024)	Cost of goods €12b (FY, 2024)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ¥1.5t (FY, 2024)	Gross profit $45.8b (FY, 2024)	Gross profit €35.8b (FY, 2024)	Gross profit N/A	Gross profit N/A
Net income	Net income ¥17b (FY, 2024)	Net income $8.1b (FY, 2024)	Net income (€2.5b) (FY, 2024)	Net income ($146.7m) (FY, 2020)	Net income N/A
Operating ⚠
Countries	Countries N/A	Countries 125 (FY, 2021)	Countries 83 (FY, 2021)	Countries N/A	Countries 126 (Jan, 2021)